- Home
- MBRX vs CCM Comparison
MBRX vs CCM Comparison
Compare MBRX & CCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- CCM
- Stock Information
- Founded
- MBRX 2015
- CCM 1997
- Country
- MBRX United States
- CCM China
- Employees
- MBRX N/A
- CCM N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- CCM Medical/Nursing Services
- Sector
- MBRX Health Care
- CCM Health Care
- Exchange
- MBRX Nasdaq
- CCM Nasdaq
- Market Cap
- MBRX 23.5M
- CCM 23.8M
- IPO Year
- MBRX 2016
- CCM 2009
- Fundamental
- Price
- MBRX $0.44
- CCM $4.60
- Analyst Decision
- MBRX Strong Buy
- CCM
- Analyst Count
- MBRX 4
- CCM 0
- Target Price
- MBRX $5.00
- CCM N/A
- AVG Volume (30 Days)
- MBRX 5.2M
- CCM 7.8K
- Earning Date
- MBRX 11-12-2025
- CCM 09-26-2025
- Dividend Yield
- MBRX N/A
- CCM N/A
- EPS Growth
- MBRX N/A
- CCM N/A
- EPS
- MBRX N/A
- CCM N/A
- Revenue
- MBRX N/A
- CCM $51,056,841.00
- Revenue This Year
- MBRX N/A
- CCM N/A
- Revenue Next Year
- MBRX N/A
- CCM N/A
- P/E Ratio
- MBRX N/A
- CCM N/A
- Revenue Growth
- MBRX N/A
- CCM N/A
- 52 Week Low
- MBRX $0.25
- CCM $3.80
- 52 Week High
- MBRX $3.65
- CCM $10.77
- Technical
- Relative Strength Index (RSI)
- MBRX 42.06
- CCM 35.79
- Support Level
- MBRX $0.46
- CCM $4.25
- Resistance Level
- MBRX $0.51
- CCM $5.77
- Average True Range (ATR)
- MBRX 0.05
- CCM 0.39
- MACD
- MBRX -0.00
- CCM -0.10
- Stochastic Oscillator
- MBRX 4.81
- CCM 15.60
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About CCM Concord Medical Services Holdings Limited
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.